Home|Journals|Articles by Year Follow on Twitter

Directory for Medical Articles
 

Open Access

Original Research

EJCM. 2021; 9(2): 94-104


The Frequency of Aspirin and Clopidogrel Resistance and Related Factors in Patients Undergoing Elective Percutaneous Coronary Intervention

Dilay Karabulut, Ayşem Kaya, Okay Abacı, Umut Karabulut, Fatma Nihan Turhan Çağlar, Alev Arat Özkan.

Abstract
Objectives: Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor is the mainstay of antithrombotic therapy after myocardial infarction (MI) and percutaneous coronary interventions (PCI). Despite chronic oral antiplatelet therapy, a number of atherothrombotic events continue to occur. Several reports in the literature have shown possible relationships between residual platelet activity and clinical outcomes, raising the possibility that ‘resistance’ to oral antiplatelet therapy may underlie such adverse events. In this study, we aimed to determine the prevalence of aspirin and clopidogrel resistance, related factors. We also aimed to identify the predictors of reduced antiplatelet response among patients undergoing elective PCI for stable coronary artery disease (CAD).
Methods: We retrospectively included patients who underwent an elective PCI with an available aggregation inhibition test results. According to aggregation inhibition test results, patients were divided into two subgroups: 1-aspirin resistant/low responders and responders 2-clopidogrel resistant /low responders and responders.
Results: Totally 470 patients with aggregation inhibition test results ( all 470 for clopidogrel and 464 for aspirin) were included in the study. Three hundred sixty-eight of them were male (78, %3). The aspirin resistance group's mean age was 60,8±10,3, clopidogrel resistance group was 58,89±10,1, and aspirin+clopidogrel resistance group was 63,25±8,8. Overall there were 164 patients with single (either aspirin or clopidogrel), and 16 (%3) patients were double resistance. Hypertension, statin use, and platelet count were found independent predictors of aspirin resistance. HL, gender, and leucocyte count were found independent predictors of clopidogrel resistance.
Conclusion: 8.1 % and 26.8 % of stable CAD patients undergoing elective PCI showed insufficient aggregation inhibition by aspirin and clopidogrel, respectively, whereas 3 % had double resistance

Key words: Aspirin, clopidogrel, resistance, percutaneous coronary intervention



Similar Articles

Synthesis of enhanced corrosion resistant Fe-B-C-Ti amorphous ribbons and evaluation of their photodegradation efficiency under light irradiation.
Zuo M, Moztahida M, Lee DS, Yi S
Chemosphere. 2022; 287(Pt 2): 132175

Percutaneous Sonographically Guided Release of Carpal Tunnel and Trigger Finger: Biomechanics, Clinical Results, Technical Developments.
Moungondo F, Feipel V
Hand clinics. 2022; 38(1): 91-100

Safe Zones for Percutaneous Carpal Tunnel Release.
Wu PT, Chern TC, Wu TT, Shao CJ, Wu KC, Kuo LC, Jou IM
Hand clinics. 2022; 38(1): 83-90

Cost-Effectiveness of Sonography-Guided Surgery.
Kinanga R, Moungondo F
Hand clinics. 2022; 38(1): 65-73

Expression of neurofibromin 1 in colorectal cancer and cetuximab resistance.
Tak E, Kim M, Cho Y, Choi S, Kim J, Han B, Kim HD, Jang CS, Kim JE, Hong YS, Kim SY, Kim TW
Oncology reports. 2022; 47(1):


Full-text options


Latest Statistics about COVID-19
• pubstat.org


Add your Article(s) to Indexes
• citeindex.org






Covid-19 Trends and Statistics
ScopeMed.com
CiteIndex.org
CancerLine
FoodsLine
PhytoMedline
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright © ScopeMed® Information Services.



ScopeMed Web Sites